JP2021080236A - Topical skin preparation - Google Patents
Topical skin preparation Download PDFInfo
- Publication number
- JP2021080236A JP2021080236A JP2019211552A JP2019211552A JP2021080236A JP 2021080236 A JP2021080236 A JP 2021080236A JP 2019211552 A JP2019211552 A JP 2019211552A JP 2019211552 A JP2019211552 A JP 2019211552A JP 2021080236 A JP2021080236 A JP 2021080236A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- salt
- solid spherical
- external preparation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 230000000699 topical effect Effects 0.000 title abstract 3
- 239000002245 particle Substances 0.000 claims abstract description 66
- 239000007787 solid Substances 0.000 claims abstract description 60
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 20
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 13
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 13
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 11
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 6
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 6
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 60
- 239000011787 zinc oxide Substances 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000002087 whitening effect Effects 0.000 claims description 13
- 239000010419 fine particle Substances 0.000 claims description 3
- 239000007854 depigmenting agent Substances 0.000 abstract 2
- 230000000052 comparative effect Effects 0.000 description 20
- -1 ascorbic acid glucoside Chemical class 0.000 description 19
- 239000011575 calcium Substances 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000002211 L-ascorbic acid Substances 0.000 description 8
- 235000000069 L-ascorbic acid Nutrition 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 7
- 239000007844 bleaching agent Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 210000002374 sebum Anatomy 0.000 description 5
- 239000002585 base Substances 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical class CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical class CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 159000000009 barium salts Chemical class 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002169 ethanolamines Chemical class 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 2
- AVWTXYWHGFHGQD-ZKCHVHJHSA-N CNC(=O)[C@H]1CC[C@H](CN)CC1 Chemical compound CNC(=O)[C@H]1CC[C@H](CN)CC1 AVWTXYWHGFHGQD-ZKCHVHJHSA-N 0.000 description 2
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- XHPXSMWMAJGYBS-UHFFFAOYSA-N 4-[[(4-carboxycyclohexyl)methylamino]methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CNCC1CCC(C(O)=O)CC1 XHPXSMWMAJGYBS-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- UEQVLKWMHAYVLO-MGCOHNPYSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)OC1=CC=C(O)C=C1C(O)=O Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)OC1=CC=C(O)C=C1C(O)=O UEQVLKWMHAYVLO-MGCOHNPYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- YQINWFJNFJEWHH-UCLHFMLVSA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O YQINWFJNFJEWHH-UCLHFMLVSA-N 0.000 description 1
- NGUBAXUPKACQCL-UCLHFMLVSA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O NGUBAXUPKACQCL-UCLHFMLVSA-N 0.000 description 1
- QDTPSCIFGGYXJD-IPKXSQMUSA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O QDTPSCIFGGYXJD-IPKXSQMUSA-N 0.000 description 1
- GAKOHFNTEXOHTP-RXSVEWSESA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O GAKOHFNTEXOHTP-RXSVEWSESA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- ULGYAEQHFNJYML-UHFFFAOYSA-N [AlH3].[Ca] Chemical compound [AlH3].[Ca] ULGYAEQHFNJYML-UHFFFAOYSA-N 0.000 description 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 229940072065 ascorbic acid 2-sulfate Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005234 chemical deposition Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940064982 ethylnicotinate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- KRDTUMQGDPZWMF-UHFFFAOYSA-N methyl 1-aminocyclohexane-1-carboxylate Chemical compound COC(=O)C1(N)CCCCC1 KRDTUMQGDPZWMF-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は、化粧料等の皮膚外用剤に関する。 The present invention relates to an external preparation for skin such as cosmetics.
白く美しい肌を実現するために種々の美白剤が開発されている。従来、このような美白剤としては、アスコルビン酸、アスコルビン酸リン酸エステル、アスコルビン酸グルコシド等のアスコルビン酸誘導体、ハイドロキノングルコシド等のハイドロキノン類の配糖体、トラネキサム酸、トラネキサム酸エステル等のトラネキサム酸類等が知られている（特許文献１）。 Various whitening agents have been developed to achieve white and beautiful skin. Conventionally, such whitening agents include ascorbic acid derivatives such as ascorbic acid, ascorbic acid phosphate and ascorbic acid glucoside, hydroquinone glycosides such as hydroquinone glucoside, tranexamic acids such as tranexamic acid and tranexamic acid ester, and the like. Is known (Patent Document 1).
しかしながら、美白剤は優れた作用を有する反面、使用感触がべたついたものになりやすいことにより、美白剤を配合した製剤は、ともすれば消費者から嫌われることが多く、皮膚外用剤、特に化粧料に配合することにおいては、大きな難点となっている。
一方、中実ガラスを化粧料に配合することが知られている（特許文献２）。
However, while whitening agents have excellent effects, they tend to be sticky to the touch, so preparations containing whitening agents are often disliked by consumers, and external preparations for skin, especially makeup, are often disliked. It is a big difficulty to mix it with the product.
On the other hand, it is known that solid glass is blended in cosmetics (Patent Document 2).
従来、皮膚外用剤に中実ガラスを配合することにより、美白剤によるべたつきを軽減することは知られていない。
本発明の一目的としては、美白剤によるべたつきが少なく、使用感の良好な皮膚外用剤を提供することである。
Conventionally, it has not been known that the stickiness caused by a whitening agent can be reduced by blending solid glass with an external preparation for skin.
An object of the present invention is to provide an external preparation for skin that is less sticky due to a whitening agent and has a good usability.
本発明者らは、かかる課題について鋭意検討した結果、本発明を完成するにいたった。すなわち本発明は、下記のとおりである。 As a result of diligent studies on such issues, the present inventors have completed the present invention. That is, the present invention is as follows.
［１］アスコルビン酸、その誘導体及びそれらの塩、ハイドロキノン、その誘導体及びそれらの塩、トラネキサム酸、その誘導体及びそれらの塩、ニコチン酸、その誘導体及びそれらの塩から選択される１種又は２種以上の美白剤と、中実球状ホウケイ酸塩粒子とを含有することを特徴とする皮膚外用剤。
［２］中実球状ホウケイ酸塩粒子が、微粒子酸化亜鉛被覆中実球状ホウケイ酸塩粒子である、［１］に記載の皮膚外用剤。
[1] One or two selected from ascorbic acid, its derivatives and their salts, hydroquinone, its derivatives and their salts, tranexamic acid, its derivatives and their salts, nicotinic acid, its derivatives and their salts. An external preparation for skin, which comprises the above whitening agent and solid spherical borosilicate particles.
[2] The external preparation for skin according to [1], wherein the solid spherical borosilicate particles are solid spherical borosilicate particles coated with fine particles of zinc oxide.
本発明の皮膚外用剤は、美白剤によるべたつきがなく、使用感が良好である皮膚外用剤を提供することができる。 The external preparation for skin of the present invention can provide an external preparation for skin that is not sticky due to a whitening agent and has a good usability.
以下、本発明を実施するための形態について詳細に説明する。ただし、本発明は以下の実施形態に限定されるものではない。 Hereinafter, embodiments for carrying out the present invention will be described in detail. However, the present invention is not limited to the following embodiments.
本発明の皮膚外用剤は、アスコルビン酸、その誘導体及びそれらの塩、ハイドロキノン、その誘導体及びそれらの塩、トラネキサム酸、その誘導体及びそれらの塩、ニコチン酸、その誘導体及びそれらの塩から選択される１種又は２種以上の美白剤を含有する。 The external preparation for skin of the present invention is selected from ascorbic acid, its derivatives and their salts, hydroquinone, its derivatives and their salts, tranexamic acid, its derivatives and their salts, nicotinic acid, its derivatives and their salts. Contains one or more whitening agents.
アスコルビン酸、その誘導体及びそれらの塩としては、皮膚外用剤に配合し得るものであれば特に限定されないが、具体的には、アスコルビン酸としては、Ｌ−アスコルビン酸、アスコルビン酸誘導体としては、Ｌ−アスコルビン酸グルコシド、Ｌ−アスコルビン酸−２−リン酸エステル、Ｌ−アスコルビン酸−３−リン酸エステル、Ｌ−アスコルビン酸−６−リン酸エステル、Ｌ−アスコルビン酸−２−ポリリン酸エステル、Ｌ−アスコルビン酸−２−硫酸エステル等のＬ−アスコルビン酸モノエステル類、Ｌ−アスコルビン酸−２−パルミチン酸エステル、Ｌ−アスコルビン酸−６−パルミチン酸エステル、Ｌ−アスコルビン酸−２−ステアリン酸エステル、Ｌ−アスコルビン酸−６−ステアリン酸エステル等のＬ−アスコルビン酸モノアルキルエステル類、 Ｌ−アスコルビン酸−２，６−ジブチルエステル、及びＬ−アスコルビン酸−２，６−ジパルミチン酸エステル等のＬ−アスコルビン酸ジアルキルエステル類、Ｌ−アスコルビン酸トリステアレート、Ｌ−アスコルビン酸トリオレエート、Ｌ−アスコルビン酸トリパルミテート等のＬ−アスコルビン酸トリアルキルエステル類、Ｌ−アスコルビン酸トリリン酸エステル等のＬ−アスコルビン酸トリエステル類、Ｌ−アスコルビルテトライソパルミテート等のＬ−アスコルビン酸テトラアルキルエステル類、アスコルビン酸及びアスコルビン酸誘導体の塩としては、ナトリウム塩、カリウム塩、マグネシウム塩、カルシウム塩、バリウム塩、アンモニウム塩、モノエタノールアミン塩、ジエタノールアミン塩、トリエタノールアミン塩、モノイソプロパノールアミン塩、及びトリイソプロパノールアミン塩等が挙げられる。この中でもアスコルビン酸２−グルコシド、リン酸アスコルビルマグネシウムを用いることが好ましい。市販品としては、ＡＡ２Ｇ（株式会社林原）、シーメート（ＢＡＳＦジャパン株式会社）、ＮＩＫＫＯＬ ＶＣ−ＰＭＧ（日光ケミカルズ株式会社）等が挙げられる。 The ascorbic acid, its derivative and a salt thereof are not particularly limited as long as they can be blended in an external preparation for skin. Specifically, ascorbic acid is L-ascorbic acid, and ascorbic acid derivative is L. -Ascorbic acid glucoside, L-ascorbic acid-2-phosphate ester, L-ascorbic acid-3-phosphate ester, L-ascorbic acid-6-phosphate ester, L-ascorbic acid-2-polyphosphate ester, L L-ascorbic acid monoesters such as −ascorbic acid-2-sulfate ester, L-ascorbic acid-2-palmitic acid ester, L-ascorbic acid-6-palmitic acid ester, L-ascorbic acid-2-stearic acid ester , L-ascorbic acid monoalkyl esters such as L-ascorbic acid-6-stearic acid ester, L-ascorbic acid-2,6-dibutyl ester, L-ascorbic acid-2,6-dipalmitic acid ester and the like. L-ascorbic acid dialkyl esters, L-ascorbic acid tristearate, L-ascorbic acid trioleate, L-ascorbic acid tripalmitate and other L-ascorbic acid trialkyl esters, L-ascorbic acid triphosphate and the like L -Ascorbic acid triesters, L-ascorbic acid tetraalkyl esters such as L-ascorbic acid tetraisopalmitate, ascorbic acid and ascorbic acid derivatives salt include sodium salt, potassium salt, magnesium salt, calcium salt, barium salt. , Ammonium salt, monoethanolamine salt, diethanolamine salt, triethanolamine salt, monoisopropanolamine salt, triisopropanolamine salt and the like. Of these, 2-glucoside ascorbic acid and magnesium ascorbyl phosphate are preferably used. Examples of commercially available products include AA2G (Hayashibara Co., Ltd.), Seamate (BASF Japan Ltd.), NIKKOL VC-PMG (Nikko Chemicals Co., Ltd.) and the like.
ハイドロキノン、その誘導体及びそれらの塩としては、皮膚外用剤に配合し得るものであれば特に限定されないが、ハイドロキノン配糖体が好適に例示される。ハイドロキノン配糖体の糖鎖部分としては、Ｌ−アラビノース、Ｄ−キシロース、Ｄ−リボース、Ｄ−キシルロース、Ｄ−リキソース、Ｄ−リブロース等の五炭糖、Ｄ−グルコース、Ｄ−ガラクトース、Ｄ−マンノース、Ｄ−タガロース、Ｄ−フルクトース、Ｌ−ソルボース等の六単糖、Ｄ−グルコサミン、Ｄ−ガラクトサミン、シアル酸、ムラミン酸等のアミノ酸糖等が例示される。また、ハイドロキノン誘導体及びそれらの塩としては、Ｄ−グルクロン酸、Ｄ−ガラクツロン酸、Ｄ−マンヌロン酸、Ｌ−イズロン酸等のウロン酸又はそれらのメチル化合物、アセチル化合物等が例示される。また、それらの塩としては、ナトリウム塩、カリウム塩、マグネシウム塩、カルシウム塩、バリウム塩、アンモニウム塩、モノエタノールアミン塩、ジエタノールアミン塩、トリエタノールアミン塩、モノイソプロパノールアミン塩、及びトリイソプロパノールアミン塩等が挙げられる。ハイドロキノン誘導体のうち、ハイドロキノンとグルコースが結合した化学構造を有するアルブチン及び／又はその塩を用いることが好ましい。市販品としては、アルブチン（日本精化株式会社）、ＡＲＵＢＴＩＮ（ＳＫ ｂｉｏｌａｎｄ Ｃｏ．，Ｌｔｄ．）等が挙げられる。 Hydroquinone, a derivative thereof, and a salt thereof are not particularly limited as long as they can be blended with an external preparation for skin, but hydroquinone glycosides are preferably exemplified. The sugar chain portion of the hydroquinone glycoside includes pentasaccharides such as L-arabinose, D-xylose, D-ribose, D-xylulose, D-lyxose, and D-ribbulose, D-glucose, D-galactose, and D-. Examples thereof include hexamonosaccharides such as mannose, D-tagalose, D-fructose, and L-sorbose, and amino acid sugars such as D-glucosamine, D-galactosamine, sialic acid, and muramic acid. Examples of hydroquinone derivatives and salts thereof include uronic acids such as D-glucuronic acid, D-galacturonic acid, D-mannuronic acid, and L-iduronic acid, or methyl compounds and acetyl compounds thereof. Examples of these salts include sodium salt, potassium salt, magnesium salt, calcium salt, barium salt, ammonium salt, monoethanolamine salt, diethanolamine salt, triethanolamine salt, monoisopropanolamine salt, and triisopropanolamine salt. Can be mentioned. Among the hydroquinone derivatives, it is preferable to use arbutin and / or a salt thereof having a chemical structure in which hydroquinone and glucose are bonded. Examples of commercially available products include arbutin (Nippon Fine Chemical Co., Ltd.), ARUBTIN (SK bioland Co., Ltd.) and the like.
トラネキサム酸、その誘導体及びそれらの塩としては、皮膚外用剤に配合し得るものであれば特に限定されないが、具体的には、トラネキサム酸誘導体としては、トラネキサム酸のアルキルアミド、エステル、多量体等が挙げられる。トラネキサム酸のアルキルアミドとしては炭素原子数１〜４のアルキルアミドが例示できる。中でも、トラネキサム酸メチルアミド（トランス−４−アミノメチルシクロヘキサンカルボン酸メチルアミド）、トラネキサム酸エチルアミド（トランス−４−アミノメチルシクロヘキサンカルボン酸メチルアミド）が好適に例示できる。炭素原子数１〜３０のアルキルエステル、炭素原子数１〜３０のアルキル基、ハロゲン原子、カルボキシル基等が置換していてもよいフェニルエステルが例示できる。中でも、４−（トランス−アミノメチルシクロヘキサンカルボン酸４'−ヒドロキシフェニルエステル、２−（トランス−４−アミノメチルシクロヘキシルカルボニルオキシ）−５−ヒドロキシ安息香酸が好適に例示できる。トラネキサム酸の多量体としては、トラネキサム酸２量体（トランス−４−（トランス−アミノメチルシクロヘキサンカルボニル）アミノメチルシクロヘキサンカルボン酸）が例示できる。また、それらの塩としては、ナトリウム塩、カリウム塩、マグネシウム塩、カルシウム塩、バリウム塩、アンモニウム塩、モノエタノールアミン塩、ジエタノールアミン塩、トリエタノールアミン塩、モノイソプロパノールアミン塩、及びトリイソプロパノールアミン塩等が挙げられる。市販品としては、トラネキサム酸（日本精化株式会社）等が挙げられる。 The tranexamic acid, its derivative, and a salt thereof are not particularly limited as long as they can be blended in an external preparation for skin. Specifically, the tranexamic acid derivative includes an alkylamide, an ester, a multimer, etc. of tranexamic acid. Can be mentioned. Examples of the alkylamide of tranexamic acid include alkylamides having 1 to 4 carbon atoms. Among them, tranexamic acid methylamide (trans-4-aminomethylcyclohexanecarboxylic acid methylamide) and tranexamic acid ethylamide (trans-4-aminomethylcyclohexanecarboxylic acid methylamide) can be preferably exemplified. Examples thereof include alkyl esters having 1 to 30 carbon atoms, phenyl esters in which alkyl groups having 1 to 30 carbon atoms, halogen atoms, carboxyl groups and the like may be substituted. Among them, 4- (trans-aminomethylcyclohexanecarboxylic acid 4'-hydroxyphenyl ester, 2- (trans-4-aminomethylcyclohexylcarbonyloxy) -5-hydroxybenzoic acid can be preferably exemplified. As a multimer of tranexamic acid. Can be exemplified by tranexamic acid dimer (trans-4- (trans-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid), and examples of these salts include sodium salt, potassium salt, magnesium salt, calcium salt, and the like. Examples thereof include barium salt, ammonium salt, monoethanolamine salt, diethanolamine salt, triethanolamine salt, monoisopropanolamine salt, and triisopropanolamine salt. Examples of commercially available products include tranexamic acid (Nippon Seika Co., Ltd.). Can be mentioned.
ニコチン酸、その誘導体及びそれらの塩としては、皮膚外用剤に配合し得るものであれば特に限定されないが、具体的には、ニコチン酸誘導体としては、ニコチン酸アミド、ニコチン酸エステルが挙げられ、エステルとしては、ニコチン酸トコフェロール、ニコチン酸ベンジル、ニコチン酸メチル、ニコチン酸エチル等が例示される。これらの中でもニコチン酸アミドを用いることが好ましい。市販品としては、ナイアシンアミドＵＳＰ ＰＣ（ロンザジャパン株式会社）、ニコチン酸アミド（ＤＳＭニュートリションジャパン株式会社）等が挙げられる。 The nicotinic acid, its derivative and a salt thereof are not particularly limited as long as they can be blended in an external preparation for skin, and specific examples of the nicotinic acid derivative include nicotinamide and nicotinic acid ester. Examples of the ester include tocopherol nicotinate, benzyl nicotinate, methyl nicotinate, ethyl nicotinate and the like. Among these, it is preferable to use nicotinamide. Examples of commercially available products include niacinamide USP PC (Lonza Japan Co., Ltd.) and nicotinamide (DSM Nutrition Japan Co., Ltd.).
本発明の皮膚外用剤は、上記の美白剤から選択される１種又は２種以上を含有することができる。
美白剤の配合量は、皮膚外用剤全量に対し、０．０００１質量％以上が好ましく、０．００１質量％以上がより好ましく、０．１質量％以上がさらに好ましい。これによって、美白効果を得ることができる。また、美白剤の配合量は、皮膚外用剤全量に対し、５質量％以下が好ましく、３質量％以下がより好ましく、１質量％以下がさらに好ましい。
例えば、美白剤の配合量は、皮膚外用剤全量に対し、０．０００１質量％〜５質量％が好ましく、０．００１質量％〜３質量％がより好ましく、０．１〜１質量％がさらに好ましい。
The external preparation for skin of the present invention may contain one or more selected from the above whitening agents.
The blending amount of the whitening agent is preferably 0.0001% by mass or more, more preferably 0.001% by mass or more, still more preferably 0.1% by mass or more, based on the total amount of the external preparation for skin. Thereby, a whitening effect can be obtained. The blending amount of the whitening agent is preferably 5% by mass or less, more preferably 3% by mass or less, and further preferably 1% by mass or less, based on the total amount of the external preparation for skin.
For example, the blending amount of the whitening agent is preferably 0.0001% by mass to 5% by mass, more preferably 0.001% by mass to 3% by mass, and further 0.1 to 1% by mass with respect to the total amount of the external preparation for skin. preferable.
本発明の皮膚外用剤は、中実球状ホウケイ酸塩粒子を含む。
中実球状ホウケイ酸塩粒子の平均粒子径は、０．１μｍ以上が好ましく、１μｍ以上がより好ましく、５μｍ以上がさらに好ましく、７μｍ以上が一層好ましい。また、中実球状ホウケイ酸塩粒子の平均粒子径は、２０μｍ以下が好ましく、１５μｍ以下がより好ましく、１３μｍ以下がさらに好ましい。例えば、中実球状ホウケイ酸塩粒子の平均粒子径は、べたつき軽減効果の観点から、好ましくは１〜２０μｍであり、より好ましくは５〜１５μｍであり、さらに好ましくは７〜１３μｍである。なお、中実球状ホウケイ酸塩粒子の平均粒子径は、粉体粒子の形状に合わせ、顕微鏡法の原理により個数平均の平均粒子径として測定することができる。
The external preparation for skin of the present invention contains solid spherical borosilicate particles.
The average particle size of the solid spherical borosilicate particles is preferably 0.1 μm or more, more preferably 1 μm or more, further preferably 5 μm or more, and even more preferably 7 μm or more. The average particle size of the solid spherical borosilicate particles is preferably 20 μm or less, more preferably 15 μm or less, and even more preferably 13 μm or less. For example, the average particle size of the solid spherical borosilicate particles is preferably 1 to 20 μm, more preferably 5 to 15 μm, and further preferably 7 to 13 μm from the viewpoint of the stickiness reducing effect. The average particle size of the solid spherical borosilicate particles can be measured as the average particle size of the number average according to the principle of microscopy according to the shape of the powder particles.
中実球状ホウケイ酸塩粒子において、ホウケイ酸塩は、Ｎａ、Ｋ等のアルカリ金属塩、Ｍｇ、Ｃａ等アルカリ土類金属塩、Ａｌ塩、又はこれらの塩の組み合わせであってよい。好ましくは、ホウケイ酸Ｎａ、ホウケイ酸Ｃａ、ホウケイ酸Ａｌ、ホウケイ酸（Ｃａ／Ｎａ）、ホウケイ酸（Ｃａ／Ａｌ）であり、より好ましくはホウケイ酸（Ｃａ／Ｎａ）である。
中実球状ホウケイ酸塩粒子は、化粧品表示名称（ＩＮＣＩ名称）としては、ホウケイ酸（Ｃａ／Ｎａ）（ＣＡＬＣＩＵＭ ＳＯＤＩＵＭ ＢＯＲＯＳＩＬＩＣＡＴＥ）、ホウケイ酸（Ｃａ／Ａｌ）（ＣＡＬＣＩＵＭ ＡＬＵＭＩＮＵＭ ＢＯＲＯＳＩＬＩＣＡＴＥ）等と表示されるが、本発明においてはいずれの表示名称の中実球状ホウケイ酸塩粒子を用いてもよく、ホウケイ酸（Ｃａ／Ｎａ）を用いることがより好ましい。
In the solid spherical borosilicate particles, the borosilicate may be an alkali metal salt such as Na or K, an alkaline earth metal salt such as Mg or Ca, an Al salt, or a combination thereof. It is preferably Na borosilicate, Ca borosilicate, Al borosilicate, borosilicate (Ca / Na), borosilicate (Ca / Al), and more preferably borosilicate (Ca / Na).
The solid spherical borosilicate particles are displayed as borosilicate (Ca / Na) (CALCIUM SODIUM BOROSILICATE), borosilicate (Ca / Al) (CALCIUM ALUMINUM BOROSILICATE), etc. as cosmetic labeling names (INCI name). In the present invention, solid spherical borosilicate particles having any display name may be used, and it is more preferable to use borosilicate (Ca / Na).
中実球状ホウケイ酸塩粒子の配合量は特に限定されないが、皮膚外用剤全量に対し、０．０１質量％以上が好ましく、０．１質量％以上がより好ましく、１質量％以上がさらに好ましい。また、中実球状ホウケイ酸塩粒子の配合量は特に限定されないが、皮膚外用剤全量に対し、３０質量％以下が好ましく、２０質量％以下がより好ましく、１０質量％以下がさらに好ましい。
例えば、中実球状ホウケイ酸塩粒子の配合量は、皮膚外用剤全量に対し、０．０１〜３０質量％が好ましく、より好ましくは０．１〜２０質量％であり、さらに好ましくは１〜１０質量％である。例えば、水媒体又は油媒体の剤型の皮膚外用剤では、中実球状ホウケイ酸塩粒子は、皮膚外用剤全量に対し０．０１〜１０質量％がさらに好ましい。また、粉末状又は固形状の剤型の皮膚外用剤では、中実球状ホウケイ酸塩粒子は、皮膚外用剤全量に対し０．１〜２０質量％がさらに好ましい。
The blending amount of the solid spherical borosilicate particles is not particularly limited, but is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, still more preferably 1% by mass or more, based on the total amount of the external preparation for skin. The blending amount of the solid spherical borosilicate particles is not particularly limited, but is preferably 30% by mass or less, more preferably 20% by mass or less, still more preferably 10% by mass or less, based on the total amount of the external preparation for skin.
For example, the blending amount of the solid spherical borosilicate particles is preferably 0.01 to 30% by mass, more preferably 0.1 to 20% by mass, and further preferably 1 to 10 with respect to the total amount of the external preparation for skin. It is mass%. For example, in an aqueous or oil-based dosage form of an external preparation for skin, the solid spherical borosilicate particles are more preferably 0.01 to 10% by mass based on the total amount of the external preparation for skin. Further, in the powdery or solid dosage form of the external preparation for skin, the solid spherical borosilicate particles are more preferably 0.1 to 20% by mass based on the total amount of the external preparation for skin.
中実球状ホウケイ酸塩粒子は未処理のものを用いてもよいし、親水化処理、又は疎水化処理を施したものを用いてもよい。 The solid spherical borosilicate particles may be untreated, or may be hydrophilized or hydrophobized.
本発明の中実球状ホウケイ酸塩粒子を皮膚外用剤に配合する場合、酸化亜鉛を被覆した酸化亜鉛被覆中実球状ホウケイ酸塩粒子とすることにより、皮脂固化効果を発揮し、化粧持ちを向上させることができる。 When the solid spherical borosilicate particles of the present invention are blended with an external preparation for skin, by using zinc oxide-coated solid spherical borosilicate particles coated with zinc oxide, a sebum solidifying effect is exhibited and makeup retention is improved. Can be made to.
本発明の酸化亜鉛被覆中実球状ホウケイ酸塩粒子に用いられる酸化亜鉛は、皮膚外用剤に配合し得るものであれば特に限定されない。酸化亜鉛の形状は特に限定されない。酸化亜鉛の平均粒子径は、皮脂固化能の観点より、１０〜２００ｎｍが好ましく、１５〜１００ｎｍがより好ましく、さらには１５〜５０ｎｍが一層好ましい。なお、酸化亜鉛の平均粒子径は、体積基準の平均粒子径であり、レーザー回折・散乱式粒度分布測定装置により測定することができる。 The zinc oxide used in the zinc oxide-coated solid spherical borosilicate particles of the present invention is not particularly limited as long as it can be blended with an external preparation for skin. The shape of zinc oxide is not particularly limited. The average particle size of zinc oxide is preferably 10 to 200 nm, more preferably 15 to 100 nm, and even more preferably 15 to 50 nm from the viewpoint of sebum solidifying ability. The average particle size of zinc oxide is a volume-based average particle size, and can be measured by a laser diffraction / scattering type particle size distribution measuring device.
酸化亜鉛被覆中実球状ホウケイ酸塩粒子は、例えば、中実球状ホウケイ酸塩粒子を酸化亜鉛粉末によって被覆することによって得ることができる。酸化亜鉛粉末には、微粒子酸化亜鉛粒子を用いることが好ましい。
酸化亜鉛は未処理の酸化亜鉛をそのまま用いることもできるが、疎水化処理を施した酸化亜鉛を用いることが好ましい。疎水化処理剤としては特に限定されるものではなく、ジメチコン、メチルハイドロジェンポリシロキサン、金属石鹸等が例示される。これらの疎水化処理剤の中でも、ジメチコンを用いることが好ましい。疎水化処理剤の被覆量は酸化亜鉛を疎水化処理するのに十分な量であればよい。具体的には酸化亜鉛と疎水化処理剤の質量比が８５：１５〜９９：１が好ましく、さらには９０：１０〜９８：２が好ましい。
The zinc oxide-coated solid spherical borosilicate particles can be obtained, for example, by coating the solid spherical borosilicate particles with zinc oxide powder. It is preferable to use fine particles of zinc oxide as the zinc oxide powder.
As the zinc oxide, untreated zinc oxide can be used as it is, but it is preferable to use zinc oxide that has been hydrophobized. The hydrophobizing agent is not particularly limited, and examples thereof include dimethicone, methylhydrogenpolysiloxane, and metal soap. Among these hydrophobizing agents, it is preferable to use dimethicone. The coating amount of the hydrophobizing agent may be an amount sufficient for hydrophobizing zinc oxide. Specifically, the mass ratio of zinc oxide to the hydrophobizing agent is preferably 85: 15-99: 1, and more preferably 90: 10-98: 2.
本発明の皮膚外用剤に用いられる酸化亜鉛被覆中実球状ホウケイ酸塩粒子において、中実球状ホウケイ酸塩粒子１質量部に対し、酸化亜鉛の被覆量は０．０１質量部以上が好ましく、０．０５質量部以上がより好ましい。また、中実球状ホウケイ酸塩粒子１質量部に対し、酸化亜鉛の被覆量は２質量部以下が好ましく、１．５質量部以下がより好ましい。この範囲で、皮脂固化能をより高めて、皮脂崩れをより防止することができる。
中実球状ホウケイ酸塩粒子１質量部に対し、酸化亜鉛の被覆量は０．０１〜２質量部が好ましく、０．０５〜１．５質量部がより好ましい。
In the zinc oxide-coated solid spherical borosilicate particles used for the external preparation for skin of the present invention, the coating amount of zinc oxide is preferably 0.01 part by mass or more with respect to 1 part by mass of the solid spherical borosilicate particles, and is 0. More preferably, it is 0.05 parts by mass or more. Further, the coating amount of zinc oxide is preferably 2 parts by mass or less, and more preferably 1.5 parts by mass or less with respect to 1 part by mass of the solid spherical borosilicate particles. In this range, the sebum solidifying ability can be further enhanced and sebum collapse can be further prevented.
The amount of zinc oxide coated is preferably 0.01 to 2 parts by mass, more preferably 0.05 to 1.5 parts by mass with respect to 1 part by mass of the solid spherical borosilicate particles.
中実球状ホウケイ酸塩への酸化亜鉛の被覆方法としては、これまで知られた各種方法を用いることができ、例えば、物理化学的な混合摩砕法（乾式、湿式）、化学的な沈着法等を用いることができる。酸化亜鉛被覆中実球状ホウケイ酸塩粒子の皮脂固化能の点から、乾式の混合摩砕法を好ましく用いることができる。 As a method for coating solid spherical borosilicate with zinc oxide, various methods known so far can be used, for example, a physicochemical mixed grinding method (dry or wet), a chemical deposition method, or the like. Can be used. From the viewpoint of sebum solidification ability of the zinc oxide-coated solid spherical borosilicate particles, a dry mixed grinding method can be preferably used.
本発明の皮膚外用剤は、上記した中実球状ホウケイ酸塩粒子、好ましくは酸化亜鉛被覆中実球状ホウケイ酸塩粒子を含むことによって、皮脂固化能を有し、優れた化粧持ち効果を発揮することができる。 The external preparation for skin of the present invention has a sebum-solidifying ability and exhibits an excellent cosmetic lasting effect by containing the above-mentioned solid spherical borosilicate particles, preferably zinc oxide-coated solid spherical borosilicate particles. be able to.
本発明の皮膚外用剤において、美白剤及び中実球状ホウケイ酸塩粒子の合計量は、皮膚外用剤全量に対し、０．１〜１０質量％が好ましく、１〜８質量％がより好ましい。
本発明の皮膚外用剤において、美白剤１質量部に対し、中実球状ホウケイ酸塩粒子は、０．０１〜１質量部が好ましく、０．０５〜０．５質量部が好ましい。この範囲で、美白剤による作用を得ながら、皮膚外用剤のべたつき及び化粧持ちを改善することができる。
In the external preparation for skin of the present invention, the total amount of the whitening agent and the solid spherical borosilicate particles is preferably 0.1 to 10% by mass, more preferably 1 to 8% by mass, based on the total amount of the external preparation for skin.
In the external preparation for skin of the present invention, the solid spherical borosilicate particles are preferably 0.01 to 1 part by mass, preferably 0.05 to 0.5 part by mass with respect to 1 part by mass of the whitening agent. Within this range, it is possible to improve the stickiness and long-lasting makeup of the external preparation for skin while obtaining the action of the whitening agent.
本発明の皮膚外用剤の剤型は特に限定されず、ルースタイプの粉末状皮膚外用剤、固形状油性皮膚外用剤、ペースト状油性皮膚外用剤、液状油性皮膚外用剤、油中水乳化型皮膚外用剤、水中油乳化型皮膚外用剤、水性皮膚外用剤、エアゾール等の剤型を採用することができる。
本発明の皮膚外用剤には、通常皮膚外用剤に配合し得る成分を配合することができる。
The dosage form of the external preparation for skin of the present invention is not particularly limited, and is a loose type external preparation for powdered skin, a solid oily external preparation for skin, a pasty external preparation for oily skin, a liquid external preparation for oily skin, and an emulsified skin in oil. Dosage forms such as external preparations, oil-in-water emulsified skin external preparations, aqueous skin external preparations, and aerosols can be adopted.
The external preparation for skin of the present invention can contain components that can be usually blended with external preparations for skin.
本発明の皮膚外用剤は、通常の製造方法により製造することができる。
例えば、皮膚外用剤は、上記した美白剤と、中実球状ホウケイ酸塩粒子と、基剤とを混合することで、製造することができる。固形状又は粉末状の皮膚外用剤には、基剤として、無機粒子、樹脂粒子等を用いることができる。液体状、乳液状、又はエマルション状の皮膚外用剤には、基剤として、水、水溶性有機溶剤、非水溶性有機溶剤等を用いることができる。
The external preparation for skin of the present invention can be produced by a usual production method.
For example, an external preparation for skin can be produced by mixing the above-mentioned whitening agent, solid spherical borosilicate particles, and a base. Inorganic particles, resin particles and the like can be used as a base for the solid or powder external preparation for skin. For the liquid, emulsion, or emulsion skin external preparation, water, a water-soluble organic solvent, a water-insoluble organic solvent, or the like can be used as a base.
以下、実施例を挙げて本発明についてより具体的に説明する。ただし、本発明は以下の実施例に限定されるものではない。なお、配合量は、特に指定しない限り質量％を意味する。比較例については、対応する実施例に配合したホウケイ酸（Ｃａ／Ｎａ）又は酸化亜鉛被覆ホウケイ酸（Ｃａ／Ｎａ）を「全量を１００とする量」と表記される成分に置換したものを対応する比較例とした。また、実施例又は比較例は定法により調製した。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to the following examples. The blending amount means mass% unless otherwise specified. As for the comparative example, the borosilicate (Ca / Na) or zinc oxide-coated borosilicate (Ca / Na) blended in the corresponding example was replaced with a component described as "amount with which the total amount is 100". It was used as a comparative example. In addition, Examples or Comparative Examples were prepared by a conventional method.
以下実施例及び比較例の評価方法について説明する。
［べたつき］
前腕内側部をあらかじめ決められた石鹸を用いて洗浄し、前腕の水分をふき取る。左右前腕に２箇所ずつ３．０ｃｍ×３．０ｃｍの領域を記し、実施例及び比較例の組成物を指サックをはめた指で隣り合わせに適量塗布し、下記の基準で合議により判定した。なお、官能評価専門員３名を被験者とした。
「○」：実施例のほうが、べたつきが少ない。
「△」：実施例、比較例が同等である。
「×」：比較例のほうが、べたつきが少ない。
The evaluation methods of Examples and Comparative Examples will be described below.
[Stickiness]
Clean the inside of the forearm with a predetermined amount of soap and wipe off the water from the forearm. Two areas of 3.0 cm × 3.0 cm were marked on the left and right forearms, and an appropriate amount of the compositions of Examples and Comparative Examples were applied side by side with fingers fitted with finger cots, and the judgment was made by consensus based on the following criteria. The subjects were three sensory evaluation specialists.
"○": The example is less sticky.
"Δ": Examples and comparative examples are equivalent.
"X": The comparative example is less sticky.
［化粧持ち］
べたつきを評価したサンプルについて、４時間後の前腕内側部に残存している実施例又は比較例を目視で観察し、下記の基準で合議により判定した。なお、官能評価専門員３名を被験者とした。
「○」：実施例のほうが、残存量が多い。
「△」：実施例、比較例が同等である。
「×」：比較例のほうが、残存量が多い。
[Makeup]
For the sample evaluated for stickiness, the examples or comparative examples remaining on the medial part of the forearm after 4 hours were visually observed and judged by consensus based on the following criteria. The subjects were three sensory evaluation specialists.
"○": The remaining amount is larger in the examples.
"Δ": Examples and comparative examples are equivalent.
"X": The comparative example has a larger residual amount.
ホウケイ酸（Ｃａ／Ｎａ）としては、商品名「ＣＯＶＡＢＥＡＤ ＣＲＹＳＴＡＬ」（ＳＥＮＳＩＥＮＴ ＣＯＳＭＥＴＩＣ ＴＥＣＨＮＯＬＯＧＩＥＳ社製；平均粒子径１１μｍ；中実球状ホウケイ酸塩粒子）を使用し、酸化亜鉛被覆ホウケイ酸（Ｃａ／Ｎａ）としては、商品名「プルセア ＣＢＺ−ＮＶ」（鈴木油脂工業株式会社製；酸化亜鉛被覆中実球状ホウケイ酸塩粒子）を使用した。 As the borosilicate (Ca / Na), the product name "COVABEAD CRYSTAL" (manufactured by SENSIENT COSMETIC TECHNOLOGIES; average particle size 11 μm; solid spherical borosilicate particles) is used, and zinc oxide-coated borosilicate (Ca / Na) is used. As, the trade name "Pulsair CBZ-NV" (manufactured by Suzuki Yushi Kogyo Co., Ltd .; zinc oxide-coated solid spherical borosilicate particles) was used.
表１、表２にパウダーファンデーションの処方例とその評価結果を示す。表１、表２に示す通り中実球状ホウケイ酸塩粒子を配合した実施例は、配合していない比較例より、べたつきの少ない良好な使用感であった。また、酸化亜鉛被覆中実球状ホウケイ酸塩粒子を配合した実施例６〜１０は、対応する比較例よりも化粧持ちがさらに良好であった。 Tables 1 and 2 show examples of powder foundation formulations and their evaluation results. As shown in Tables 1 and 2, the examples in which the solid spherical borosilicate particles were blended had a better usability with less stickiness than the comparative examples in which the solid spherical borosilicate particles were not blended. In addition, Examples 6 to 10 containing the zinc oxide-coated solid spherical borosilicate particles had even better makeup retention than the corresponding comparative examples.
表３、表４に水中油型乳化リキッドファンデーションの処方例とその評価結果を示す。表３、表４に示した通り中実球状ホウケイ酸塩粒子を配合した実施例は、配合していない比較例よりべたつきの少ない良好な使用感であった。また、酸化亜鉛被覆中実球状ホウケイ酸を配合した実施例１６〜２０は、対応する比較例よりも化粧持ちが良好であった。 Tables 3 and 4 show formulation examples of the oil-in-water emulsified liquid foundation and their evaluation results. As shown in Tables 3 and 4, the examples in which the solid spherical borosilicate particles were blended had a better usability with less stickiness than the comparative examples in which the solid spherical borosilicate particles were not blended. In addition, Examples 16 to 20 containing zinc oxide-coated solid spherical borosilicate had better makeup retention than the corresponding comparative examples.
表５に化粧下地の処方例とその評価結果を示す。表５に示した通り中実球状ホウケイ酸塩粒子を配合した実施例は、配合していない比較例よりべたつきの少ない良好な使用感であった。 Table 5 shows a prescription example of the makeup base and its evaluation result. As shown in Table 5, the example in which the solid spherical borosilicate particles were blended had a better feeling of use with less stickiness than the comparative example in which the solid spherical borosilicate particles were not blended.
表６、表７に油中水型乳化日焼け止めの処方例とその評価結果を示す。表６、表７に示した通り中実球状ホウケイ酸塩粒子を配合した実施例は、配合していない比較例よりべたつきの少ない良好な使用感であった。また、酸化亜鉛被覆中実球状ホウケイ酸塩粒子を配合した実施例３１〜３５は、対応する比較例よりも化粧持ちがさらに良好であった。 Tables 6 and 7 show prescription examples of water-in-oil emulsified sunscreens and their evaluation results. As shown in Tables 6 and 7, the examples in which the solid spherical borosilicate particles were blended had a better feeling of use with less stickiness than the comparative examples in which the solid spherical borosilicate particles were not blended. In addition, Examples 31 to 35 containing zinc oxide-coated solid spherical borosilicate particles had even better cosmetic retention than the corresponding Comparative Examples.
表８に乳液の処方例とその評価結果を示す。表８に示した通り中実球状ホウケイ酸塩粒子を配合した実施例は、配合していない比較例よりべたつきの少ない良好な使用感であった。 Table 8 shows prescription examples of emulsions and their evaluation results. As shown in Table 8, the example in which the solid spherical borosilicate particles were blended had a better feeling of use with less stickiness than the comparative example in which the solid spherical borosilicate particles were not blended.
表９にクリームの処方例とその評価結果を示す。表９に示した通り中実球状ホウケイ酸塩粒子を配合した実施例は、配合していない比較例よりべたつきの少ない良好な使用感であった。 Table 9 shows examples of cream prescriptions and their evaluation results. As shown in Table 9, the examples in which the solid spherical borosilicate particles were blended had a better usability with less stickiness than the comparative examples in which the solid spherical borosilicate particles were not blended.
表１０にクレンジングクリームの処方例とその評価結果を示す。表１０に示した通り中実球状ホウケイ酸塩粒子を配合した実施例は、配合していない比較例よりべたつきの少ない良好な使用感であった。 Table 10 shows a prescription example of the cleansing cream and its evaluation result. As shown in Table 10, the example in which the solid spherical borosilicate particles were blended had a better feeling of use with less stickiness than the comparative example in which the solid spherical borosilicate particles were not blended.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019211552A JP2021080236A (en) | 2019-11-22 | 2019-11-22 | Topical skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019211552A JP2021080236A (en) | 2019-11-22 | 2019-11-22 | Topical skin preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2021080236A true JP2021080236A (en) | 2021-05-27 |
Family
ID=75966128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019211552A Pending JP2021080236A (en) | 2019-11-22 | 2019-11-22 | Topical skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2021080236A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7521726B2 (en) | 2021-08-04 | 2024-07-24 | 株式会社中村超硬 | Hydroquinone-supported zeolite |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007077087A (en) * | 2005-09-15 | 2007-03-29 | Noevir Co Ltd | Pearlescent pigment |
| JP2015182958A (en) * | 2014-03-20 | 2015-10-22 | ポーラ化成工業株式会社 | base makeup cosmetics |
| JP2016190835A (en) * | 2015-03-30 | 2016-11-10 | 株式会社コーセー | Oil-in-water type cosmetic |
| JP2019019077A (en) * | 2017-07-18 | 2019-02-07 | ポーラ化成工業株式会社 | Skin external composition |
-
2019
- 2019-11-22 JP JP2019211552A patent/JP2021080236A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007077087A (en) * | 2005-09-15 | 2007-03-29 | Noevir Co Ltd | Pearlescent pigment |
| JP2015182958A (en) * | 2014-03-20 | 2015-10-22 | ポーラ化成工業株式会社 | base makeup cosmetics |
| JP2016190835A (en) * | 2015-03-30 | 2016-11-10 | 株式会社コーセー | Oil-in-water type cosmetic |
| JP2019019077A (en) * | 2017-07-18 | 2019-02-07 | ポーラ化成工業株式会社 | Skin external composition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7521726B2 (en) | 2021-08-04 | 2024-07-24 | 株式会社中村超硬 | Hydroquinone-supported zeolite |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20000048522A (en) | Liquid personal cleansing compositions which contain oils and synthetic surfactants | |
| JP2008524264A (en) | Flushing personal care composition containing high modulus lipids | |
| WO2004100922A1 (en) | Personal care compositions that deposit shiny particles | |
| KR101552588B1 (en) | Liquid cosmetic | |
| JP2010168302A (en) | Emulsified cosmetic | |
| JP5495810B2 (en) | Non-aqueous warm skin cleansing composition | |
| JP2006282632A (en) | Solid state water-in-oil type emulsion cosmetic | |
| JP6057461B2 (en) | Alpha gel structure and cosmetic or skin external preparation containing the same | |
| JP4563194B2 (en) | Composition for external use | |
| JP5897803B2 (en) | Creamy skin cleanser | |
| EP1408912B1 (en) | Temperature insensitive one-phase microemulsions | |
| JP2021080236A (en) | Topical skin preparation | |
| JP6012426B2 (en) | Oily liquid cleansing cosmetic | |
| JP2013075867A (en) | Multilayer type cosmetic | |
| JP6820463B2 (en) | Topical skin and anti-wrinkle agents | |
| BR112015032654B1 (en) | fluid and foamy personal care composition and method for forming a fluid and foamable personal care composition | |
| JP2009234993A (en) | Water-in-oil emulsion composition containing salicylic acid or salicylic acid derivative | |
| JP2019214564A (en) | Solubilized skin detergent composition | |
| JP2021091643A (en) | Topical skin preparation | |
| JP2021080229A (en) | Topical skin preparation | |
| JP6847839B2 (en) | Cleansing composition with fast rinsing speed | |
| JP2002370986A (en) | Sugar uptake promoter | |
| JP2013028550A (en) | Oil-based cosmetic | |
| JP5856761B2 (en) | External preparation for skin and method for producing the same | |
| JP2010013382A (en) | Detergent composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220823 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230619 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230627 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231025 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231219 |